Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several muscle-related statements are consistent with the label’s myopathy/rhabdomyolysis warning language, but multiple claims (e.g., “myopathy” definition, “muscle mass loss,” “decreased muscle protein synthesis,” and manufacturer-report wording) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Supported by label class/mechanism context (Section 12.1 indicates Lipitor is an HMG-CoA reductase inhibitor; Section 5.1 refers to “other statins”).
Lipitor (atorvastatin) can cause muscle pain and weakness.
Supported: Section 5.1 states myopathy is defined as “muscle aches or muscle weakness …” and notes that atorvastatin, like other statins, occasionally causes myopathy.
Statin use can cause muscle damage.
Partially supported by Section 5.1 describing myopathy and rhabdomyolysis; provided excerpt supports skeletal muscle injury risk terminology at a general level.
There are reports of muscle mass loss associated with statin use, including Lipitor.
Not supported in the provided excerpts (see unsupported statements).
Lipitor's manufacturer, Pfizer, has received reports of myopathy associated with the medication.
Not supported in the provided excerpts.
Lipitor's manufacturer, Pfizer, has received reports of rhabdomyolysis associated with the medication.
Not supported in the provided excerpts.
Unsupported Statements
Muscle pain and weakness caused by Lipitor is known as myopathy.
While Section 5.1 defines myopathy as muscle aches or muscle weakness with CPK >10x ULN, the provided excerpt does not state that muscle pain/weakness “caused by Lipitor” is known as myopathy as a standalone definitional equation; the definition is conditional (with CPK elevation).
There are reports of muscle mass loss associated with statin use, including Lipitor.
The provided label excerpts discuss myopathy and rhabdomyolysis but do not mention muscle mass loss.
Statin use can decrease muscle protein synthesis.
The provided excerpts do not mention muscle protein synthesis.
Decreased muscle protein synthesis may contribute to muscle mass loss.
The provided excerpts do not mention muscle protein synthesis or muscle mass loss.
Lipitor's manufacturer, Pfizer, has received reports of myopathy associated with the medication.
The provided excerpts do not include pharmacovigilance language about manufacturer reports.
Lipitor's manufacturer, Pfizer, has received reports of rhabdomyolysis associated with the medication.
The provided excerpts do not include pharmacovigilance language about manufacturer reports.
Contradictions
Important Omissions
No label-grounded details were provided about the label-defined laboratory criterion for myopathy (CPK >10x ULN) and related management language (temporarily withholding/discontinuing for acute serious myopathy risk conditions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some muscle adverse effects (myopathy; rhabdomyolysis risk) are consistent with the label excerpt, but unsupported mechanistic claims (muscle mass loss, muscle protein synthesis) and unsupported manufacturer-report wording may mislead interpretation of what the label actually states.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Several statements are not supported by the provided label excerpts, particularly those about muscle mass loss, decreased muscle protein synthesis, and manufacturer report language.
Suggested Improvement
Restrict muscle-related claims to what the label excerpts support (myopathy definition including the CPK criterion and the occurrence of rare rhabdomyolysis) and avoid mechanistic claims or manufacturer-report statements unless present in the label excerpts provided.